Study #2021-0158
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells ([DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells {CABA-201]) in subjects with active, pemphigus vulgaris.
MD Anderson Study Status
Enrolling
Treatment Agent
DSG3-CAART or CABA-201
Description
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pemphigus Vulgaris
Study phase:
Phase I
Physician name:
Omar Pacha
Department:
Dermatology
For general questions about clinical trials:
1-833-644-2296
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.